Global, regional and national burden of liver cancer 1990–2021: a systematic analysis of the global burden of disease study 2021

• Published in: BMC public health Vol. 25; no. 1; pp. 931 - 21
• Main Authors: Jiang, Zhichao, Zeng, Guoqiang, Dai, Huajia, Bian, Yuhao, Wang, Libin, Cao, Wei, Yang, Junfeng
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 08.03.2025; BioMed Central; BMC
• Subjects: Adult; Age; Aged; Analysis; Cancer; Care and treatment; Cost of Illness; DALYs; Data; Data envelopment analysis; Diagnosis; Disability-Adjusted Life Years; Disease; Disease prevention; Estimates; Female; Frontier analysis; Geospatial data; Global Burden of Disease - trends; Global health; Global Health - statistics & numerical data; Health care access; Health care policy; Health policy; Hepatitis; Humans; Liver cancer; Liver cirrhosis; Liver diseases; Liver Neoplasms - epidemiology; Liver Neoplasms - mortality; Male; Medical treatment; Middle Aged; Mortality; Mortality rates; Policy making; Prevalence; Prevalence studies (Epidemiology); Public health; Regions; Registration; Regression analysis; Remission (Medicine); Risk factors; Socio-demographic index; Sociodemographics; Spatial data; Time trends (Statistics); Trends; China; Japan; Frontier analysis; Socio-demographic index; Global health; Liver cancer; Prevalence; DALYs
• DOI: 10.1186/s12889-025-22026-6
• ISSN: 1471-2458

Liver cancer is a growing global health issue, with significant geographical disparities in prevalence and mortality. Understanding these differences is key to developing effective prevention and treatment strategies. We analyzed liver cancer trends from 1990 to 2021 across 204 countries using data from the Global Burden of Disease (GBD) study. We modeled mortality from vital registration data and estimated non-fatal burden using primary studies, hospital discharges, and claims data. We calculated prevalence, mortality, YLLs, YLDs, and DALYs, adjusting for age and reporting rates per 100,000 population with 95% UI. In 2021, there were 739,299 (673114-821948) cases of liver cancer worldwide. The age-standardized prevalence rate increased from (7.75 [6.91-8.43] per 100,000 people) in 1990 to (8.68[7.90-9.67] per 100,000 people) in 2021, while the mortality rate slightly decreased from(4.48 [4.10-4.93] per 100,000 people) to (6.13 [5.58-6.84] per 100,000 people). High-income North America had the highest prevalence rate, and Southern Latin America had the lowest. Mongolia had the highest prevalence and mortality rates, while Morocco had the lowest. The total YLDs attributed to liver cancer nearly tripled from 1990 to 2021, and the age-standardized DALY rate decreased. In the frontier analysis, countries or regions with higher SDI have greater potential for burden improvement. In the frontier analysis of SDI and age-standardized liver cancer DALY rates in 2021, countries with higher SDI (> 0.85) and higher effective differences relative to their level of development include America, Canada, Germany, Netherlands, etc., while frontier countries with lower SDI (< 0.5) and lower effective differences include Somalia, Papua New Guinea, Yemen, Lao People's Democratic Republic, etc. Countries with larger effective differences include Togo, Gambia, Australia, Norway, etc. CONCLUSION: The global burden of liver cancer is decreasing, but the prevalence of liver cancer is increasing, with significant differences across regions worldwide. These findings can inform health policy and research to address this global challenge. From 1990 to 2021, the incidence of liver cancer in many regions has increased significantly, which is expected to impose a huge social and economic burden on governments and health systems in the coming years. Our research findings may assist policymakers in devising strategies to combat liver cancer, including educating professionals to address the burden of this complex disease.